A large multicenter study provides robust support for avoiding head CT scans in children at low risk.
A robust clinical decision rule for identifying children with head trauma who are at low risk for intracranial injury could eliminate unnecessary radiation exposure from computed tomography (CT) scans. In a multicenter North American study, researchers enrolled 42,412 children (age, ≤18 years) with mild head trauma (defined as Glasgow Coma Scale score >13) to derive and validate decision rules for two age groups: <2 years and ≥2 years.
The study outcome was complicated head trauma (defined as neurosurgery, death from traumatic brain injury, intubation for >24 hours, or hospital admission for ≥2 nights). The investigators defined rules (based on a derivation group of children) for avoiding CT in the two age groups (see table).
In the validatio…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals